scholarly journals Second-Line Immunosuppressive Treatment of Childhood Nephrotic Syndrome: A Single-Center Experience

Nephron Extra ◽  
2014 ◽  
Vol 4 (1) ◽  
pp. 8-17 ◽  
Author(s):  
J. Kim ◽  
N. Patnaik ◽  
N. Chorny ◽  
R. Frank ◽  
L. Infante ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Immunosuppressive Treatment ◽  
Second Line ◽  
Single Center ◽  
Childhood Nephrotic Syndrome ◽  
Single Center Experience

scholarly journals Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience

2013 ◽  
Vol 35 (3) ◽  
pp. 200-205 ◽  
Author(s):  
Catalina Velez Echeverri ◽  
Gustavo Adolfo Zuluaga Valencia ◽  
Lina Maria Serna Higuita ◽  
Ana Katherina Serrano Gayubo ◽  
Carolina Lucia Ochoa ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Single Center ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome ◽  
Single Center Experience ◽  
Immunosupressive Therapy

Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis

2016 ◽  
Vol 65 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Hai-Dong Fu ◽  
Gu-Ling Qian ◽  
Zheng-yang Jiang
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Meta Analysis ◽  
Immunosuppressive Agents ◽  
Second Line ◽  
Childhood Nephrotic Syndrome ◽  
Randomized Controlled ◽  
Search Terms ◽  
October 17 ◽  
Refractory Nephrotic Syndrome

Although, most patients respond initially to therapy for nephrotic syndrome, about 70% of patients have a relapse. Currently, there is no consensus about the most appropriate second-line agent in children who continue to suffer a relapse. This network meta-analysis was designed to compare the efficacy and safety of the commonly used immunosuppressive agents in second-line therapeutic agents (ie, cyclophosphamide, cyclosporine, tacrolimus and mycophenolate mofetil) for refractory childhood nephrotic syndrome. MEDLINE, Cochrane, EMBASE and Google Scholar databases were searched until October 17, 2015 using the following search terms: cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil and childhood nephrotic syndrome. Randomized controlled trials, prospective 2-arm studies and cohort studies were included. 7 studies with 391 patients were included. Bayesian network meta-analysis found that treatment with mycophenolate mofetil had the greatest odds of relapse compared with tacrolimus (pooled OR=49.72, 95% credibility interval (CrI) 1.65 to 2483.32), cyclophosphamide (pooled OR=72.05, 95% CrI 1.44 to 13633.33) and cyclosporine (pooled OR=11.42, 95% CrI 1.03 to 131.60). Rank probability analysis found cyclophosphamide was the best treatment with the lowest relapse rate as compared with other treatments (rank probability=0.58), and tacrolimus was ranked as the second best (rank probability=0.38). Our findings support the use of cyclophosphamide and tacrolimus in treating children with relapsing nephrotic syndrome.

MO291RITUXIMAB IS EFFECTIVE AND SAFE IN ADULTS WITH STEROID-DEPENDENT NEPHROTIC SYNDROME: A LONG-TERM, SINGLE-CENTER EXPERIENCE

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Gemma Patella ◽  
Alessandro Comi ◽  
Giuseppe Coppolino ◽  
Nicolino Comi ◽  
Giorgio Fuiano ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Case Series ◽  
Adult Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Steroid Dependent ◽  
The Mean ◽  
Steroid Dependent Nephrotic Syndrome

Abstract Background and Aims Steroid-dependent nephrotic syndrome (SDNS) may require a prolonged multi-drug therapy with risk of drug toxicity and renal failure. Rituximab (RTX) treatment has been found to be helpful in reducing the steroid dosage and the need for immunosuppressants (ISs), but little data are currently available regarding very long-term outcomes in adults. We herein describe a long-term, single-center experience of RTX use in a large series of adults with SDNS. Method We studied 23 adult patients with SDNS (mean age 54.2±17.1 y; 65% male; BMI 28.5±4.7), mostly consequent to membranous (47.8%) or focal glomerulonephritis (30.2 %) who were eligible to start a RTX regimen. Before entering the RTX protocol, proteinuria and eGFR were 7.06±3.87 g/24h and 65.9±28.2 ml/min/1.73 m2, respectively; albumin and CD19/CD20 ratio were 2.9±0.9 g/L and 0.99±0.01 respectively; the mean number of ISs was 2.39±0.89 and the mean annual rate of relapses was 2.2±0.9. Results Patients were followed over a mean follow-up of 64 months (range: 12-144). After RTX (mean dose: 1202.1±372.4 mg) the rate of relapses was virtually nullified (p<0.001). eGFR remained roughly stable (62.1±19.8 ml/min/1.73 m2, p=NS), while proteinuria, albumin, CD19/CD20 and BMI all significantly improved (p ranging from 0.01 to 0.001). The mean number of additional ISs was also reduced (0.44±0.12; p<0.001) and RTX enabled discontinuation of steroids in 13/23 (56.5%) patients. No major adverse events related to therapy were recorded. Conclusion Findings from this large case-series with a remarkable very long follow-up reinforce the role of RTX as an efficient and safe weapon to improve outcomes in adult patients suffering from SDNS.

Association between serious immune-related adverse events and survival in patients with advanced HCC treated by nivolumab: A single-center experience.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16661-e16661
Author(s):  
Antonia Digklia ◽  
Antonella Diciolla ◽  
Arnaud Hocquelet
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Palliative Therapy ◽  
Rank Test ◽  
P Value ◽  
Second Line ◽  
Single Center ◽  
Advanced Hcc ◽  
Entire Cohort ◽  
Single Center Experience

e16661 Background: Nivolumab received accelerated approval by the FDA in 2017 for the treatment of advanced hepatocellular carcinomas (HCC). This study is aimed at evaluating the relationship between serious irAEs leading to treatment pause and survival of patients treated with nivolumab in our center. Methods: we performed a retrospective analysis of the patients treated at our center. The Kaplan Meir method was used to evaluate overall survival(OS). Log-rank test was conducted to compare groups in terms of OS. Adverse events were assessed using NCI CTCAE version 4.03 criteria. Results: Twenty patients with advanced HCC received nivolumab as palliative therapy between 2017-2019. 12/20 received nivolumab as first line treatment, 7/20 as second line. 6/20 patients stopped nivolumab due to serious irAEs including pancreatitis, kidney dysfunction and colitis leading to definitively stop of the therapy. The majority of patients received nivolumab in second line (5/6). The 1 year OS was 44% at the non-serious irAEs group and 84% in the serious irAEs group (p value = 0.0166). Median overall survival for the entire cohort was 11.4 months. The median OS was 8.11 months in patients without serious irAEs and 18.2 months in the group with toxicity. Conclusions: the occurrence of serious irAEs was associated with longer OS at our single center review. These results are in line with reports in other diseases such as lung cancer and melanoma. These retrospective data warrant further evaluation.

scholarly journals Mycophenolate Mofetil Treatment in Childhood Steroid-sensitive Nephrotic Syndrome: Single Center Experience

2021 ◽  
pp. 1-5
Author(s):  
Tülin GÜNGÖR ◽  
Fehime KARA EROĞLU ◽  
Evrim KARGIN ÇAKICI ◽  
Fatma YAZILITAŞ ◽  
Gökçe CAN ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Single Center ◽  
Single Center Experience ◽  
Steroid Sensitive Nephrotic Syndrome ◽  
Steroid Sensitive
Sign in / Sign up

Export Citation Format

Share Document